...Good morning, everyone, and thank you for joining us. We're excited to be speaking with you fresh off a highly successful American Epilepsy Society Meeting for Xenon. Before we begin, please note the standard notice that we will make a number of statements today that are forward-looking. I encourage you to review our SEC filings for a more complete discussion of risks facing our business and readers are cautioned not to place undue reliance on such forward-looking statements. After today's call, a recording of this presentation will be available on the Investors section of our website at xenon-pharma.com. So joining me on today's call are Dr. Chris Kenney, our Chief Medical Officer; Darren Cline, our Chief Commercial Officer; and Tucker Kelly, our Chief Financial Officer. I'm going to start today with some opening remarks, including an overview of our presence at the recent meeting of the American Epilepsy Society. And what we heard from clinicians about the opportunity for azetukalner...
